Drawing on a rich scientific heritage and extensive international research, Gylden has developed collaborations in the US, EU, Singapore and Brazil with leading vaccine research bodies, including George Mason University in the US, the Institute of Molecular and Cell Biology (IMCB) of Singapore, and Brazil-based IBMP (Molecular Biology Institute of Paraná)/Bio-Manguinhos/Fiocruz.

Gylden will consider further collaboration and partnerships to accelerate its pipeline of vaccine and immunotherapy candidates.

Please contact info@gyldenpharma.com to discuss opportunities with Gylden Pharma and to arrange a meeting.